Wells Fargo raised the firm’s price target on GeneDx (WGS) to $105 from $75 and keeps an Equal Weight rating on the shares. The firm notes the company exited the year on a high note, with material upside to Q4 revenues and EBITDA. 2025 revenue guide was +5% above consensus, but still leaves room for upside from higher exome/genome ASPs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx price target raised to $135 from $118 at TD Cowen
- GeneDx Reports Strong 2024 Growth and 2025 Outlook
- GeneDx Holdings: Strong Buy Rating Backed by Impressive Q4 Results and 2025 Growth Potential
- GeneDx Highlights Strong Growth in Earnings Call
- GeneDx Holdings: Strong Q4 Performance and Strategic Growth Justify Buy Rating